Mojca Jensterle, Rok Herman, Andrej Janež, Wael Al Mahmeed, Khalid Al-Rasadi, Kamila Al-Alawi, Maciej Banach, Yajnavalka Banerjee, Antonio Ceriello, Mustafa Cesur, Francesco Cosentino, Massimo Galia, Su-Yen Goh, Sanjay Kalra, Peter Kempler, Nader Lessan, Paulo Lotufo, Nikolaos Papanas, Ali A Rizvi, Raul D Santos, Anca P Stoian, Peter P Toth, Vijay Viswanathan, Manfredi Rizzo
Coronavirus disease 2019 (COVID-19) is a highly heterogeneous disease regarding severity, vulnerability to infection due to comorbidities, and treatment approaches. The hypothalamic-pituitary-adrenal (HPA) axis has been identified as one of the most critical endocrine targets of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that might significantly impact outcomes after infection. Herein we review the rationale for glucocorticoid use in the setting of COVID-19 and emphasize the need to have a low index of suspicion for glucocorticoid-induced adrenal insufficiency, adjusting for the glucocorticoid formulation used, dose, treatment duration, and underlying health problems...
June 30, 2022: International Journal of Molecular Sciences